Susan O'Brien

13PUBLICATIONS
10CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Adolescent health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 13, 2018
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

Hagop M Kantarjian, Courtney D DiNardo, Graciela M Nogueras-Gonzalez

|Jan 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Elias J Jabbour, Daniel J DeAngelo, Matthias Stelljes

|Dec 22, 2017
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.

Koji Sasaki, Hagop Kantarjian, Susan O'Brien

|Jul 26, 2017
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.

Preetesh Jain, Hagop M Kantarjian, Ahmad Ghorab

|Jul 15, 2017
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.

Elias Jabbour, Nicholas J Short, Farhad Ravandi

|Jun 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.

Rashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi

Pageof 3

Frequent Collaborators

4 joint publications

Koji Sasaki

4 joint publications

Naval G Daver

4 joint publications

Tapan M Kadia

3 joint publications

Hagop M Kantarjian